

<p style="text-align: center;"><b>PATIENT CARD</b> <b>VANFLYTA®</b> quizaritinib</p> <ul style="list-style-type: none"> <li>• Please keep this card with you at all times.</li> <li>• This card contains important safety information that you should know before you take VANFLYTA and during treatment with VANFLYTA.</li> <li>• Show this card to any doctor, pharmacist or surgeon before any medical intervention or treatment.</li> </ul>	<p style="text-align: center;">   <b>Daiichi-Sankyo</b>  <small>IE 122375</small> </p> <p style="text-align: center;">  This medicinal product is subject to additional monitoring.         </p> <p style="text-align: center;"> <b>For more information, please read the package leaflet.</b> </p> <p>This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See the Patient Information Leaflet for how to report side effects.</p>	<p> <ul style="list-style-type: none"> <li>• You suffer from diarrhoea or vomiting, or are unable to eat or drink fluids in sufficient amounts.</li> <li>• You feel any other sudden change in your well-being.</li> <li>• Your medicines are changed by a healthcare professional other than the doctor who prescribed VANFLYTA.</li> </ul> </p> <p>Consult your doctor first before taking VANFLYTA with any other medicines, including medicines obtained without a prescription or supplementary products as these may increase the risk of you developing QT interval prolongation.</p>	<p style="text-align: center;"><b>Contact your doctor immediately if:</b></p> <ul style="list-style-type: none"> <li>• You are feeling dizzy, lightheaded or faint.</li> <li>• You sense a change in heart rhythm, e.g., palpitations or an abnormality of your pulse. You may feel your heart is beating too fast, but you may also sense a more nonspecific or vague change.</li> <li>• You have fainted or have been unconscious, even if it was only for a very short period of time, e.g., seconds.</li> </ul>	<p style="text-align: center;"><b>Important information for the patient</b></p> <p>VANFLYTA can cause an abnormal electrical activity in your heart called "prolonged QT interval" which may lead to a life-threatening disturbance of the heart rhythm. Therefore, a regular check of the electrical activity in your heart with an electrocardiogram (ECG) is very important.</p>
<p><b>Patient information</b></p> <p>Patient name: .....</p> <p>Date of birth: .....</p> <p>In case of emergency, please contact:</p> <p>Name: .....</p> <p>Phone number: .....</p>	<p><b>Treatment information</b> (To be completed by healthcare professional or patient)</p> <p>VANFLYTA has been prescribed at a once-daily dose of: .....</p> <p>..... mg</p> <p>Started on: .....</p> <p>..... / ..... (mm/yy)</p>	<p><b>Prescriber information</b> (To be completed by healthcare professional or patient)</p> <p>For more information or in case of emergency, please contact:</p> <p>Doctor's name: .....</p> <p>Phone number: .....</p>	<p><b>Important information for healthcare professionals</b></p> <p>VANFLYTA is associated with QT interval prolongation, which may increase the risk of ventricular arrhythmias or torsade de pointes.</p> <ul style="list-style-type: none"> <li>• Interrupt VANFLYTA if QTcF is <math>\geq 501</math> ms and permanently discontinue if associated with torsade de pointes, polymorphic ventricular tachycardia or signs/symptoms of life-threatening arrhythmia. VANFLYTA is contraindicated in patients with congenital long QT syndrome.</li> </ul>	<ul style="list-style-type: none"> <li>• During VANFLYTA treatment, check serum electrolytes and correct any hypokalaemia and hypomagnesaemia as needed.</li> <li>• Avoid non-essential medicines that prolong the QT interval. If unavoidable, monitor ECG frequently.</li> <li>• The dose of VANFLYTA should be reduced when used concomitantly with strong CYP3A inhibitors.</li> </ul> <p><b>For more information, please see the Summary of Product Characteristics (SmPC).</b></p>